Calithera Biosciences, Inc. (NASDAQ:CALA) – Analysts at Leerink Swann boosted their FY2017 EPS estimates for shares of Calithera Biosciences in a research report issued to clients and investors on Thursday, Zacks Investment Research reports. Leerink Swann analyst J. Chang now forecasts that the biotechnology company will post earnings of ($0.76) per share for the year, up from their previous forecast of ($0.95). Leerink Swann also issued estimates for Calithera Biosciences’ Q4 2017 earnings at ($0.23) EPS.
A number of other research firms have also recently issued reports on CALA. BidaskClub cut Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. William Blair assumed coverage on Calithera Biosciences in a research report on Thursday, October 5th. They set an “outperform” rating for the company. Finally, Zacks Investment Research raised Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Monday, November 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $15.17.
ILLEGAL ACTIVITY WARNING: This article was reported by Week Herald and is the property of of Week Herald. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://weekherald.com/2017/11/15/leerink-swann-comments-on-calithera-biosciences-inc-s-fy2017-earnings-cala.html.
Calithera Biosciences (CALA) opened at $9.40 on Monday. Calithera Biosciences has a 52 week low of $2.90 and a 52 week high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.02 million.
A number of large investors have recently added to or reduced their stakes in CALA. State Street Corp raised its stake in Calithera Biosciences by 5,802.1% in the second quarter. State Street Corp now owns 1,304,375 shares of the biotechnology company’s stock valued at $19,370,000 after buying an additional 1,282,275 shares during the period. FMR LLC raised its stake in Calithera Biosciences by 85.8% in the second quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock valued at $40,349,000 after buying an additional 1,254,900 shares during the period. Vanguard Group Inc. raised its stake in Calithera Biosciences by 99.8% in the first quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock valued at $10,684,000 after buying an additional 462,137 shares during the period. Northern Trust Corp raised its stake in Calithera Biosciences by 1,355.1% in the second quarter. Northern Trust Corp now owns 337,640 shares of the biotechnology company’s stock valued at $5,014,000 after buying an additional 314,436 shares during the period. Finally, American Century Companies Inc. raised its stake in Calithera Biosciences by 272.8% in the third quarter. American Century Companies Inc. now owns 424,752 shares of the biotechnology company’s stock valued at $6,690,000 after buying an additional 310,806 shares during the period. Hedge funds and other institutional investors own 71.88% of the company’s stock.
In related news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $15.64, for a total transaction of $9,008,640.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 16.30% of the company’s stock.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.